leadf
logo-loader
viewBraveheart Investment Group

Braveheart Investment Group's Paraytec completes proof of concept Covid-19 trials with Sheffield Uni

Braveheart Investment Group PLC (LON:BRH) recently announced that their investee Paraytec Limited has completed proof of concept trials for a coronavirus test it is developing with the University of Sheffield.

Joining Proactive London to discuss the test and how it compares to other concepts, is Professor Carl Smythe from the University of Sheffield, who is working on this test.

Smythe says this test distinguishes itself by establishing whether someone is 'intact' of the virus (rather than fragments that are lingering after infection) and the timescale in which results can be achieved will be 'very fast'.

Quick facts: Braveheart Investment Group

Price: 37 GBX

AIM:BRH
Market: AIM
Market Cap: £13.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Braveheart Investment Group Pharm2Farm designs antiviral face mask to kill...

Braveheart Investment Group PLC (LON:BRH) investee company Pharm2Farm's (P2F) Gareth Cave talks to Proactive London about their new antiviral face mask that can kill coronavirus (COVID-19). Cave talks through the technology behind the mask, which is says is much stronger than the standard...

on 26/10/20

2 min read